Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GALR1 | P47211 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022466 | 0.90 | POLB (0.56) | POLBTP53HPGDGALR1RAB9A | |
| SCHEMBL11223090 | 0.85 | TP53 (0.59) | POLBTP53HPGDGALR1RAB9A | |
| SCHEMBL29617015 | 0.82 | TP53 (0.62) | POLBTP53HPGDGALR1RAB9A | |
| SCHEMBL5096355 | 0.82 | TP53 (0.51) | POLBTP53HPGDGALR1RAB9A | |
| SCHEMBL13830820 | 0.82 | CYP4F2 (0.51) | POLBTP53HPGDGALR1CYP4F2 | |
| SCHEMBL5114049 | 0.81 | POLB (0.53) | POLBTP53HPGDGALR1RAB9A | |
| SCHEMBL13830587 | 0.81 | TP53 (0.50) | POLBTP53HPGDGALR1RAB9A | |
| SCHEMBL4193217 | 0.80 | TP53 (0.61) | POLBTP53HPGDGALR1CYP4F2 | |
| SCHEMBL6225292 | 0.80 | KDM4E (0.57) | POLBTP53HPGDGALR1CYP4F2 | |
| SCHEMBL5114415 | 0.80 | TP53 (0.49) | POLBTP53HPGDGALR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1742916-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108369-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | PTGER1, PTGER2, PTGDR | POLB 3146/4885TP53 4639/4885HPGD 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.